Several studies suggest that mutations of isocitrate dehydrogenases (IDH1/2), which represent one of the main characteristics of glioma cells and occur at specific codons in IDH1 and IDH2, are attractive candidates for glioma immunotherapy (164, 165). Here, IDH3A is linked to central nervous system cancer.